
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is in a strong position with its clinical-stage candidate gedatolisib, which offers comprehensive inhibition of the PI3K/AKT/mTOR pathway. The company has completed enrollment and reported positive results for PIK3CA WT tumors in its Phase 3 VIKTORIA-1 trial, with plans to submit data for PIK3CA MT patients in Q3 2026. Celcuity also has ongoing Phase 3 and Phase 1b/2 trials targeting endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer.The company plans to launch gedatolisib at a competitive price of $10,000 per vial, with expected gross-to-net discounts of 20%. Updated safety data and mean treatment duration analyses from the Phase 3 VIKTORIA-1 trial will be submitted to regulatory agencies in Q3 2026, supporting potential global approval. Celcuity has a solid track record of successful regulatory submissions, and they have already submitted data for publication in a medical journal, suggesting confidence in the potential for NCCN guideline incorporation. Despite some risks to their investment thesis, Celcuity is expected to have a successful commercial launch for gedatolisib in 2027, with projected peak sales of $
Bears say
Celcuity is currently in the clinical stage of developing gedatolisib, a potential first-in-class pan-PI3K inhibitor. While management has expressed confidence in their ability to begin commercial shipments in late-3Q26 and the initiation of an Expanded Access Program should help with patient on-boarding, concerns remain about the potential rate-limiting treatment durations and dose intensity. In addition, the targeted therapy space is highly competitive and there is no guarantee of commercial success for gedatolisib. The upcoming mutant sNDA submission and potential additional data on both wild-type and mutant patients will be key catalysts to watch. The company reported no revenues for the quarter and has a net loss of $4.84 per diluted share projected for FY2026, with a current cash balance that management believes is sufficient to fund operations into 2029.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares